Metamizol Pensa (Metamizole Magnesium)

Metamizole magnesium works by non‑selectively inhibiting cyclooxygenase enzymes, which lowers prostaglandin production and reduces inflammation‑related pain. It also influences central nervous system pathways, including spinal opioid receptors and the hypothalamic thermoregulatory center, providing both analgesic and antipyretic effects.

The appropriate dose of Metamizol Pensa is determined by the prescribing clinician based on the patient’s condition, severity of symptoms, age, renal function, and other individual factors. Healthcare professionals adjust the regimen to achieve optimal pain or fever control while monitoring for safety.

Safety data for metamizole magnesium during pregnancy and lactation are limited, and the drug is generally classified as contraindicated or to be used only when clearly needed. Physicians should weigh potential benefits against possible risks and consider alternative therapies when treating pregnant or nursing individuals.

To place an order, submit an enquiry on the Metamizol Pensa product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with non‑steroidal anti‑inflammatory drugs (NSAIDs), metamizole offers strong analgesic and antipyretic effects with less gastrointestinal irritation but carries a risk of rare blood disorders. Unlike opioids, it does not produce typical opioid‑related respiratory depression, making it a useful alternative for certain acute pain scenarios.

Metamizol Pensa should be stored at ambient temperature, below 25 °C, in its original container to protect it from moisture and direct sunlight. Keep the product out of reach of children and avoid exposing it to extreme heat or humidity, which could affect its stability.

Metamizol Pensa is administered orally. The tablet or oral suspension should be taken with a full glass of water, preferably after a meal to reduce gastrointestinal discomfort. Patients should follow the dosing instructions provided by their healthcare professional and not exceed the prescribed amount.

The most serious risks include agranulocytosis, a potentially fatal drop in neutrophil count that can lead to severe infections, as well as rare but severe skin reactions such as Stevens‑Johnson syndrome and life‑threatening anaphylaxis. Prompt medical attention is required if signs of these conditions appear.

Metamizol Pensa should be avoided in individuals with known hypersensitivity to metamizole or other pyrazolones, patients with a history of severe blood dyscrasias, and those currently receiving other myelosuppressive therapies. Caution is also advised for patients with severe renal impairment or uncontrolled hypertension.